nicardipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1909	55985-32-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nicardipine (+/-)-Nicardipine perpidine nicardipine hydrochloride nicardipine HCl	A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. Molecular weight: 479.53 Formula: C26H29N3O6 CLOGP: 5.23 LIPINSKI: 1 HAC: 9 HDO: 1 TPSA: 111.01 ALOGS: -5.29 ROTB: 11 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nicardipine
(+/-)-Nicardipine
perpidine
nicardipine hydrochloride
nicardipine HCl

A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.

Molecular weight: 479.53
Formula: C26H29N3O6
CLOGP: 5.23
LIPINSKI: 1
HAC: 9
HDO: 1
TPSA: 111.01
ALOGS: -5.29
ROTB: 11

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
90	mg	O
90	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	7.90 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.17 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	23 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	11 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 21, 1988	FDA	CHIESI USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral vasoconstriction	140.58	23.99	31	6250	961	50597882
Premature delivery	121.20	23.99	59	6222	23604	50575239
Hyponatraemia	120.88	23.99	98	6183	96041	50502802
Acute kidney injury	117.99	23.99	143	6138	227915	50370928
Hepatocellular injury	90.52	23.99	50	6231	25897	50572946
Posterior reversible encephalopathy syndrome	84.86	23.99	40	6241	14888	50583955
Hyperkalaemia	82.36	23.99	59	6222	48030	50550813
Acute motor-sensory axonal neuropathy	81.72	23.99	16	6265	272	50598571
Acute pulmonary oedema	79.63	23.99	31	6250	7236	50591607
Eosinophilia	79.27	23.99	41	6240	18611	50580232
Cerebral haemorrhage	67.59	23.99	42	6239	27010	50571833
Cholestasis	64.89	23.99	40	6241	25361	50573482
Hypotension	64.21	23.99	109	6172	235360	50363483
Low birth weight baby	64.12	23.99	25	6256	5856	50592987
Exposure during pregnancy	60.92	23.99	75	6206	120940	50477903
Bradycardia	57.31	23.99	54	6227	64372	50534471
Lactic acidosis	52.71	23.99	39	6242	33316	50565527
Hyperlactacidaemia	51.85	23.99	17	6264	2416	50596427
Hemivertebra	48.01	23.99	9	6272	120	50598723
Acute generalised exanthematous pustulosis	47.88	23.99	23	6258	8915	50589928
Orthostatic hypotension	47.77	23.99	35	6246	29446	50569397
Haemangioma congenital	47.45	23.99	11	6270	428	50598415
Premature baby	47.14	23.99	29	6252	18308	50580535
Haemorrhagic transformation stroke	46.28	23.99	13	6268	1096	50597747
Maternal exposure during pregnancy	46.19	23.99	76	6205	159702	50439141
Fall	45.05	23.99	116	6165	334816	50264027
Drug interaction	44.85	23.99	85	6196	199536	50399307
Hypokalaemia	43.38	23.99	54	6227	87938	50510905
Purpura	42.71	23.99	22	6259	9889	50588954
Drug reaction with eosinophilia and systemic symptoms	42.15	23.99	32	6249	28392	50570451
Thrombocytopenia	41.37	23.99	64	6217	127609	50471234
Fatigue	40.12	23.99	19	6262	707582	49891261
Congenital choroid plexus cyst	39.72	23.99	9	6272	316	50598527
Rash maculo-papular	39.52	23.99	30	6251	26611	50572232
Paradoxical drug reaction	37.98	23.99	15	6266	3632	50595211
Ischaemic stroke	37.90	23.99	24	6257	15924	50582919
Premature labour	36.96	23.99	21	6260	11455	50587388
Subarachnoid haemorrhage	35.46	23.99	20	6261	10756	50588087
Foetal growth restriction	35.33	23.99	17	6264	6610	50592233
Pain	35.22	23.99	14	6267	578889	50019954
Hepatic cytolysis	34.95	23.99	18	6263	8085	50590758
Haematoma	33.88	23.99	29	6252	30481	50568362
Rhabdomyolysis	33.32	23.99	32	6249	38995	50559848
Arthralgia	33.27	23.99	7	6274	438695	50160148
Metabolic encephalopathy	33.07	23.99	15	6266	5106	50593737
Anaphylactic shock	32.81	23.99	24	6257	20131	50578712
Renal failure	32.51	23.99	52	6229	106581	50492262
Patent ductus arteriosus	30.53	23.99	13	6268	3807	50595036
Tumour rupture	30.42	23.99	6	6275	106	50598737
Cutaneous lupus erythematosus	28.87	23.99	11	6270	2420	50596423
Foetal exposure during pregnancy	28.34	23.99	25	6256	27334	50571509
Respiratory distress	27.93	23.99	26	6255	30463	50568380
Hypertrophic cardiomyopathy	27.06	23.99	9	6272	1336	50597507
Toxic skin eruption	26.90	23.99	17	6264	11234	50587609
Altered state of consciousness	26.74	23.99	22	6259	21888	50576955
Haemodynamic instability	26.69	23.99	15	6266	8009	50590834
Pre-eclampsia	26.66	23.99	15	6266	8029	50590814
Acquired haemophilia	26.26	23.99	8	6273	895	50597948
Intra-abdominal haematoma	25.77	23.99	9	6272	1548	50597295
Mixed liver injury	25.14	23.99	11	6270	3440	50595403
Wrong patient received product	25.00	23.99	9	6272	1691	50597152
Sinus bradycardia	24.45	23.99	17	6264	13166	50585677
Metabolic acidosis	24.39	23.99	27	6254	38798	50560045

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral vasoconstriction	108.75	20.15	20	4380	196	29569931
Blood lactic acid	87.51	20.15	18	4382	328	29569799
Foetal disorder	83.08	20.15	20	4380	763	29569364
Neutropenia neonatal	76.02	20.15	18	4382	639	29569488
Acute kidney injury	70.30	20.15	134	4266	265133	29304994
Premature baby	69.78	20.15	39	4361	17241	29552886
Ureteric compression	67.38	20.15	13	4387	168	29569959
Low birth weight baby	56.95	20.15	25	4375	6583	29563544
Cerebral haemorrhage	55.04	20.15	42	4358	31384	29538743
Haematoma muscle	45.85	20.15	13	4387	944	29569183
Antiphospholipid antibodies positive	44.51	20.15	10	4390	280	29569847
Pyelocaliectasis	43.95	20.15	13	4387	1096	29569031
Foetal exposure during pregnancy	36.05	20.15	34	4366	33833	29536294
Cholestasis	35.96	20.15	29	4371	23433	29546694
Phlebitis deep	32.14	20.15	5	4395	15	29570112
Drug reaction with eosinophilia and systemic symptoms	31.52	20.15	29	4371	27963	29542164
Rash maculo-papular	30.98	20.15	27	4373	24262	29545865
Extravasation	30.94	20.15	11	4389	1661	29568466
Haemorrhagic transformation stroke	29.61	20.15	10	4390	1296	29568831
Bradycardia	29.16	20.15	42	4358	65587	29504540
Paradoxical drug reaction	29.01	20.15	12	4388	2729	29567398
Eosinophilia	29.00	20.15	25	4375	22136	29547991
Hepatic cytolysis	28.75	20.15	17	4383	8330	29561797
Thalamus haemorrhage	28.70	20.15	9	4391	923	29569204
Hyperkalaemia	28.32	20.15	40	4360	61352	29508775
Kidney small	26.74	20.15	5	4395	54	29570073
Brain herniation	25.76	20.15	12	4388	3621	29566506
Ventricular tachycardia	22.75	20.15	22	4378	22552	29547575
Haemorrhagic cerebral infarction	22.15	20.15	7	4393	736	29569391
Mixed liver injury	21.77	20.15	9	4391	2042	29568085
Respiratory gas exchange disorder	21.16	20.15	6	4394	435	29569692
Injection site oedema	20.81	20.15	5	4395	189	29569938
Blood fibrinogen decreased	20.70	20.15	7	4393	911	29569216
Fatigue	20.28	20.15	11	4389	316810	29253317

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cerebral vasoconstriction	233.35	19.31	51	10214	1171	64487296
Acute kidney injury	166.27	19.31	273	9992	448967	64039500
Cerebral haemorrhage	106.73	19.31	78	10187	51012	64437455
Eosinophilia	97.84	19.31	66	10199	38010	64450457
Cholestasis	92.57	19.31	68	10197	44804	64443663
Hyperkalaemia	91.85	19.31	96	10169	101033	64387434
Hepatocellular injury	89.83	19.31	67	10198	45168	64443299
Hyponatraemia	89.51	19.31	114	10151	148225	64340242
Blood lactic acid	81.06	19.31	18	10247	445	64488022
Acute motor-sensory axonal neuropathy	72.03	19.31	16	10249	396	64488071
Bradycardia	69.93	19.31	90	10175	118129	64370338
Haemorrhagic transformation stroke	67.68	19.31	22	10243	2367	64486100
Ureteric compression	66.35	19.31	13	10252	170	64488297
Posterior reversible encephalopathy syndrome	64.31	19.31	42	10223	22904	64465563
Paradoxical drug reaction	63.71	19.31	27	10238	6093	64482374
Hepatic cytolysis	63.56	19.31	35	10230	14014	64474453
Drug reaction with eosinophilia and systemic symptoms	63.18	19.31	59	10206	54158	64434309
Rash maculo-papular	60.30	19.31	54	10211	46972	64441495
Acute pulmonary oedema	55.45	19.31	31	10234	12778	64475689
Fatigue	51.02	19.31	28	10237	748702	63739765
Hypotension	49.67	19.31	153	10112	380821	64107646
Premature delivery	47.19	19.31	32	10233	18557	64469910
Pyelocaliectasis	46.68	19.31	13	10252	825	64487642
Lactic acidosis	46.47	19.31	53	10212	61357	64427110
Ischaemic stroke	44.64	19.31	37	10228	28998	64459469
Hypokalaemia	44.61	19.31	74	10191	121829	64366638
Purpura	42.15	19.31	29	10236	17217	64471250
Haematoma	42.10	19.31	44	10221	46206	64442261
Mixed liver injury	40.43	19.31	19	10246	5462	64483005
Acute generalised exanthematous pustulosis	40.04	19.31	26	10239	14032	64474435
Altered state of consciousness	39.88	19.31	39	10226	37863	64450604
Exposure during pregnancy	39.55	19.31	55	10210	77620	64410847
Hyperlactacidaemia	39.50	19.31	18	10247	4826	64483641
Renal failure	39.03	19.31	88	10177	181600	64306867
Pain	38.67	19.31	20	10245	553491	63934976
Haematoma muscle	36.94	19.31	13	10252	1780	64486687
Orthostatic hypotension	36.48	19.31	41	10224	46697	64441770
Fall	35.03	19.31	145	10120	416681	64071786
Thrombocytopenia	34.98	19.31	96	10169	223705	64264762
Subarachnoid haemorrhage	33.68	19.31	26	10239	18412	64470055
Respiratory distress	32.73	19.31	41	10224	52290	64436177
Phlebitis deep	32.33	19.31	5	10260	13	64488454
Premature labour	31.78	19.31	18	10247	7602	64480865
Antiphospholipid antibodies positive	30.97	19.31	9	10256	666	64487801
Haemorrhagic cerebral infarction	28.89	19.31	10	10255	1304	64487163
Brain herniation	28.79	19.31	16	10249	6517	64481950
Cardiac arrest	28.05	19.31	70	10195	153994	64334473
Thrombotic microangiopathy	27.23	19.31	22	10243	16633	64471834
Thalamus haemorrhage	26.85	19.31	10	10255	1609	64486858
Pulmonary hypoplasia	26.40	19.31	5	10260	54	64488413
Anaphylactic shock	26.08	19.31	28	10237	30300	64458167
Drug interaction	25.84	19.31	120	10145	361963	64126504
Confusional state	25.24	19.31	95	10170	261049	64227418
Dizziness	25.23	19.31	19	10246	430144	64058323
Cutaneous lupus erythematosus	25.17	19.31	11	10254	2671	64485796
Haemodynamic instability	25.02	19.31	20	10245	14892	64473575
Vasoplegia syndrome	24.84	19.31	11	10254	2756	64485711
Maternal exposure during pregnancy	24.66	19.31	50	10215	95834	64392633
Pre-eclampsia	24.06	19.31	14	10251	6217	64482250
Metabolic encephalopathy	23.24	19.31	15	10250	8010	64480457
Acquired haemophilia	23.24	19.31	9	10256	1611	64486856
Arthralgia	22.92	19.31	22	10243	442238	64046229
Foetal growth restriction	22.66	19.31	9	10256	1721	64486746
Rhabdomyolysis	22.60	19.31	47	10218	91679	64396788
Toxic skin eruption	22.47	19.31	21	10244	19263	64469204
Agranulocytosis	22.40	19.31	29	10236	38200	64450267
Tumour rupture	21.95	19.31	6	10259	355	64488112
Hypertrophic cardiomyopathy	21.91	19.31	9	10256	1877	64486590
Brain contusion	21.82	19.31	8	10257	1231	64487236
Ventricular tachycardia	21.67	19.31	27	10238	34238	64454229
Peripheral swelling	20.85	19.31	4	10261	209149	64279318
Headache	20.46	19.31	33	10232	529434	63959033
Weight decreased	20.39	19.31	10	10255	285729	64202738
Porphyria	20.19	19.31	5	10260	200	64488267
Enterobacter sepsis	19.86	19.31	7	10258	962	64487505
Cerebral haematoma	19.75	19.31	13	10252	7172	64481295
Intra-abdominal haematoma	19.54	19.31	9	10256	2470	64485997
Gestational hypertension	19.45	19.31	8	10257	1673	64486794
Metabolic acidosis	19.44	19.31	38	10227	70920	64417547

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA04	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
FDA CS	M0006414	Dihydropyridines
FDA MoA	N0000000069	Calcium Channel Antagonists
FDA EPC	N0000175421	Dihydropyridine Calcium Channel Blocker
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:38215	calcium channel blockers
CHEBI has role	CHEBI:88230	autophagy inhibitors
CHEBI has role	CHEBI:176497	geroprotectors
FDA MoA	N0000182137	Cytochrome P450 2D6 Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	indication	194828000
Prinzmetal angina	off-label use	87343002
Raynaud's phenomenon	off-label use	266261006
Portal hypertension	contraindication	34742003	DOID:10762
Low blood pressure	contraindication	45007003
Chronic heart failure	contraindication	48447003
Chronic idiopathic constipation	contraindication	82934008
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Cerebral hemorrhage	contraindication	274100004
Cerebral infarction	contraindication	432504007	DOID:3526
Severe Aortic Valve Stenosis	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.02	Basic
pKa2	2.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
20MG/200ML (0.1MG/ML)	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
20MG/200ML (0.1MG/ML)	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	July 31, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	RX	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	DISCN	INJECTABLE	INTRAVENOUS	7659291	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	RX	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
40MG/200ML (0.2MG/ML)	CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER	CHIESI	N019734	Nov. 7, 2008	DISCN	INJECTABLE	INTRAVENOUS	8455524	April 18, 2027	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER			CHEMBL	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.32	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.49	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	4.78	CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.55	WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		Ki	5.55	WOMBAT-PK
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.30	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.38	WOMBAT-PK
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	4.71	CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	4.20	CHEMBL
Adenosine receptor A3	GPCR		AA3R_RAT		Ki	4.96	CHEMBL
Equilibrative nucleoside transporter 1	Transporter		S29A1_RAT		Ki	5.27	CHEMBL
Quinolone resistance protein NorA	Transporter		NORA_STAAU		IC50	4.64	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		IC50	5.85	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	5.44	CHEMBL
Voltage-gated L-type calcium channel	Ion channel		CAC1C_RAT CAC1D_RAT CAC1S_RAT		Ki	9.08	CHEMBL
Potassium voltage-gated channel subfamily A member 4	Ion channel		KCNA4_RAT	BLOCKER	IC50	6.10	IUPHAR

External reference:

ID	Source
4019858	VUID
N0000147944	NUI
D00617	KEGG_DRUG
54527-84-3	SECONDARY_CAS_RN
4019350	VANDF
4019858	VANDF
C0028005	UMLSCUI
CHEBI:7550	CHEBI
CHEMBL1484	ChEMBL_ID
CHEMBL1200326	ChEMBL_ID
D009529	MESH_DESCRIPTOR_UI
DB00622	DRUGBANK_ID
2559	IUPHAR_LIGAND_ID
4745	INN_ID
CZ5312222S	UNII
4474	PUBCHEM_CID
235230	RXNORM
2278	MMSL
5171	MMSL
d00315	MMSL
000712	NDDF
004518	NDDF
108526002	SNOMEDCT_US
108527006	SNOMEDCT_US
372502001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9542	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9542	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9593	INJECTION	2.50 mg	INTRAVENOUS	NDA	26 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9633	INJECTION	0.20 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9633	INJECTION	0.20 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9634	INJECTION	0.10 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9634	INJECTION	0.10 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9689	INJECTION	25 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9689	INJECTION	25 mg	INTRAVENOUS	NDA	27 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1020	CAPSULE	20 mg	ORAL	ANDA	22 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1430	CAPSULE	30 mg	ORAL	ANDA	22 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-0735	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	ANDA	26 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	0781-3204	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	0781-9324	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-313	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	23 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-314	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	23 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	10122-325	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	23 sections
Nicardipine Hydrochloride	Human Prescription Drug Label	1	14593-124	INJECTION	2.50 mg	INTRAVENOUS	ANDA	12 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24658-750	CAPSULE	20 mg	ORAL	ANDA	19 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24658-751	CAPSULE	30 mg	ORAL	ANDA	19 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	40042-047	INJECTION, SOLUTION	2.50 mg	INTRAVENOUS	ANDA	20 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-501	CAPSULE	20 mg	ORAL	ANDA	19 sections
Nicardipine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42806-502	CAPSULE	30 mg	ORAL	ANDA	19 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-009	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-016	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	24 sections
CARDENE IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-016	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	24 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-021	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-021	INJECTION, SOLUTION	0.10 mg	INTRAVENOUS	NDA	24 sections
Cardene IV	HUMAN PRESCRIPTION DRUG LABEL	1	43066-024	INJECTION, SOLUTION	0.20 mg	INTRAVENOUS	NDA	24 sections